Sign in
Taking people in South KoreaPhase 3

Tests elecoglipron for weight management in adults with obesity or overweight

Tests elecoglipron against placebo in adults with excess weight, with or without diabetes.

Key facts

Who runs it
AstraZeneca
Where
Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, and Suwon, South KoreaSee the 8 sitesAlso in 18 other countries, 262 sites
Registry title
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Status
Recruiting
Phase
Phase 3
People taking part
4,500 people, planned
Started
29 Jun 2026
Expected to end
30 Jul 2029
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Elecoglipron
  • Placebo
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity or overweight and at least one weight-related health problem. Study 1 is for people without type 2 diabetes (T2DM). Study 2 is for people with T2DM.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Study 1: BMI 30 kg/m2 or more, or BMI from 25 kg/m2 to under 30 kg/m2 with high blood pressure, prediabetes, abnormal blood fats, heart or blood vessel disease, or sleep apnea. Study 2: BMI 25 kg/m2 or more and T2DM (diagnosed, or HbA1c 6.5% (48 mmol/mol) or higher at screening).
Earlier treatment
Body weight must have been stable for 90 days before screening (within 5% change). People must have tried at least once, without success, to lose weight by diet.
Biomarker or test result
Study 2 only: HbA1c 6.5% (48 mmol/mol) or higher at screening if T2DM was not diagnosed before.

Main reasons for not taking part

  • Study 1: diagnosed type 1 or type 2 diabetes
  • Study 2: type 1 diabetes
  • Study 2: HbA1c 10% (86 mmol/mol) or higher at screening
  • Study 2: treatment for diabetic eye disease, or more than one severe low blood sugar episode in the past 180 days
  • Past or present pancreatitis (some exceptions), or medullary thyroid cancer or multiple endocrine neoplasia type 2 in the person or close family

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Legal age of consent and at least 18 years old
  • Study 1 -; BMI ≥ 30 kg/m2 or; 25 kg/m2 ≤ BMI < 30 kg/m2 with at least one of the following weight-related comorbidities:; Hypertension; Prediabetes; Dyslipidemia; Cardiovascular disease; Obstructive sleep apnea
  • Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:; Established diagnosis of T2DM; Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit
  • Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

Who cannot take part

  • History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
  • History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2
  • Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:; T1DM; HbA1c ≥ 10% (86 mmol/mol) at the screening visit; Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • Study 1 - Established diagnosis of T1DM or T2DM

Where in South Korea

Also in 18 other countries, 262 sites

  • BusanHospital not named in the registryNo longer taking part
  • DaeguHospital not named in the registryNot yet recruiting
  • Goyang-siHospital not named in the registryTaking people
  • Gyeonggi-doHospital not named in the registryTaking people
  • IncheonHospital not named in the registryTaking people
  • Jongno-guHospital not named in the registryTaking people
  • SeoulHospital not named in the registryNot yet recruiting
  • SuwonHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

The 3 groups in the trial

  • Arm 1 - Dose 1Treatment being tested

    Active IMP

    Treatment: Elecoglipron

  • Arm 2 - Dose 2Treatment being tested

    Active IMP

    Treatment: Elecoglipron

  • Arm 3 - PlaceboPlacebo, for comparison

    Placebo matching elecoglipron

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
Plain-language title
Tests elecoglipron for weight management in adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 October 2026